Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Immunovant (IMVT – Research Report) yesterday and set a price target of $52.00. The company’s shares closed last Friday at $41.48.
According to TipRanks, Thompson CFA is a 4-star analyst with an average return of 10.8% and a 63.41% success rate. Thompson CFA covers the Healthcare sector, focusing on stocks such as Argenx Se, MoonLake Immunotherapeutics, and Travere Therapeutics.
Immunovant has an analyst consensus of Strong Buy, with a price target consensus of $50.75, implying a 22.35% upside from current levels. In a report released on December 21, Piper Sandler also assigned a Buy rating to the stock with a $57.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $44.70 and a one-year low of $14.05. Currently, Immunovant has an average volume of 2.46M.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IMVT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunovant (IMVT) Company Description:
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
Read More on IMVT:
- Immunovant price target raised to $52 from $47 at Stifel
- Immunovant price target raised to $51 from $49 at BofA
- Immunovant price target raised to $51 from $47 at H.C. Wainwright
- Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
- Immunovant announces results from initial cohort of batoclimab trial
